PMID- 36936033
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230321
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Print)
IS  - 1792-1074 (Linking)
VI  - 25
IP  - 4
DP  - 2023 Apr
TI  - Evaluation of the therapeutic effects and tolerability of modified lenvatinib 
      administration methods for unresectable hepatocellular carcinoma: A preliminary 
      study.
PG  - 150
LID - 10.3892/ol.2023.13736 [doi]
LID - 150
AB  - Lenvatinib (LEN), a multitarget tyrosine kinase inhibitor, is a standard 
      therapeutic agent for hepatocellular carcinoma, but the high incidence of adverse 
      events (AEs) related to LEN treatment often necessitates treatment 
      discontinuation. The present study aimed to clarify the therapeutic efficacy and 
      tolerability of modified LEN dosing methods, such as alternate-day dosing, 
      necessitated by AEs of LEN. A total of 66 patients who received LEN at Ogaki 
      Municipal Hospital (Ogaki, Japan) between April 2018 and January 2022 were 
      retrospectively evaluated. These patients were divided into those who completed 
      treatment with the standard administration method (standard LEN, n=48) and those 
      who changed from the standard administration method to a modified administration 
      method in the middle of treatment [modified LEN (weekends off/alternate days), 
      n=18]. The treatment duration and reasons for discontinuation of LEN treatment 
      were analysed. The discontinuation rate due to AEs in the modified LEN group (1 
      patient) was less compared with that in the standard LEN group (16 patients) 
      (P=0.022). The median treatment duration for patients in the standard LEN (n=48), 
      modified LEN (weekends off, n=6) and modified LEN (alternate days, n=12) groups 
      was 71 [95% confidence interval (CI) 55-134], 483 (95% CI: 193-644) and 222 (95% 
      CI: 98-303) days, respectively (P=0.044). Modification of the administration 
      method ensured fewer AE-related treatment discontinuations. However, weekends off 
      dosing showed a longer treatment duration compared with standard dosing, whereas 
      alternate day dosing showed no difference from standard dosing.
CI  - Copyright (c) 2023, Spandidos Publications.
FAU - Kimura, Michio
AU  - Kimura M
AD  - Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Gifu 503-8502, Japan.
FAU - Go, Makiko
AU  - Go M
AD  - Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Gifu 503-8502, Japan.
FAU - Yamada, Shiori
AU  - Yamada S
AD  - Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Gifu 503-8502, Japan.
FAU - Asano, Hiroki
AU  - Asano H
AD  - Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Gifu 503-8502, Japan.
FAU - Usami, Eiseki
AU  - Usami E
AD  - Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Gifu 503-8502, Japan.
FAU - Yoshimura, Tomoaki
AU  - Yoshimura T
AD  - Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Gifu 503-8502, Japan.
LA  - eng
PT  - Journal Article
DEP - 20230303
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC10018281
OTO - NOTNLM
OT  - adverse event
OT  - duration of treatment
OT  - hepatocellular carcinoma
OT  - ingenuity of administration method
OT  - lenvatinib
OT  - unresectable
COIS- The authors declare that they have no competing interests.
EDAT- 2023/03/21 06:00
MHDA- 2023/03/21 06:01
PMCR- 2023/03/03
CRDT- 2023/03/20 03:39
PHST- 2022/12/07 00:00 [received]
PHST- 2023/01/27 00:00 [accepted]
PHST- 2023/03/20 03:39 [entrez]
PHST- 2023/03/21 06:00 [pubmed]
PHST- 2023/03/21 06:01 [medline]
PHST- 2023/03/03 00:00 [pmc-release]
AID - OL-25-4-13736 [pii]
AID - 10.3892/ol.2023.13736 [doi]
PST - epublish
SO  - Oncol Lett. 2023 Mar 3;25(4):150. doi: 10.3892/ol.2023.13736. eCollection 2023 
      Apr.